CVS: while pharmacists & techs are walking off the job because of grossly under staffed- stock prices SURGE HIGHER

CVS Health (CVS) Hits a 52-Week High: What’s Driving It?

https://finance.yahoo.com/news/cvs-health-cvs-hits-52-160404360.html

CVS Health Corporation CVS reached a new 52-week high of $107.61 on Jan 27, before closing the session marginally lower at $106.79.

The company’s shares have charted a solid trajectory in recent times, appreciating 49.1% over the past year, ahead of the 28.7% rise of the industry it belongs to and 17.5% surge of the S&P 500 composite.

Over the past five years, the company registered earnings growth of 8.1%, ahead of the industry’s 6.1% rise and the S&P 500’s 2.8% increase. The company’s long-term expected growth rate of 7.8% compares with the industry’s growth projection of 6.1% and the S&P 500’s estimated 11.7% increase.

CVS Health has been registering robust growth across three of its operating segments. The company’s retail/long term care (LTC) business witnessed a substantial recovery in front store sales, raising investors’ confidence. Strong potential in the specialty pharmacy space also instills optimism. A good solvency position is another plus.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Let’s delve deeper.

Key Drivers

Segmental Growth: The market is upbeat about enhanced third-quarter revenues across three of CVS Health’s operating segments. Within pharmacy services, growth outperformed the company’s expectations, delivering 9.3% revenue growth and strong operating income growth. The retail/LTC segment reported above-market growth and exceeded the company’s expectations with 10% revenue growth. Meanwhile, in the health care benefits arm, CVS Health registered 9.5% revenue growth, strongly driven by growth in the government business.

Retail on a Growth Track: Over the last few quarters, CVS Health’s retail/LTC business has been registering revenue growth after several quarters of a drag. In the third quarter, the segment’s pharmacy sales and prescriptions filled increased 8% year over year, largely driven by COVID-19 vaccine administration and core pharmacy services. The company also witnessed a solid rebound in front store sales on strength across all categories, with health and wellness products driving nearly two-thirds of growth. The company’s patient satisfaction scores remained high, with nearly 90% satisfied with their experience in CVS Health locations.

Specialty Pharmacy – A High-Growth Avenue: The soaring demand for specialty pharmacy, especially in the ongoing decade, is likely to accelerate growth for CVS Health. In the third quarter, specialty pharmacy revenues increased 8.7%, reflecting integrated offering with in-store, mail order and specialty services growth. The company also saw continued growth within specialty pharmacy capabilities. Furthermore, CVS Health’s investments in high-growth areas of specialty pharmacy, adding businesses such as Coram and Novologix, raise our optimism.

Strong Solvency: CVS Health ended the third quarter with cash and cash equivalents of $9.8 billion compared with $10.13 billion at the end of the second quarter. Total debt came up to $58.39 billion, much higher than the corresponding cash and cash equivalent level. Yet, the near-term payable debt of $1.5 million is significantly lower than the short-term cash level, indicating good news in terms of the company’s solvency level. The company is holding sufficient cash for debt repayment, at least for the year of economic downturn.

Downsides

A host of factors have been deterring CVS Health’s rally of late.

The ongoing difficult pharmaceutical reimbursement scenario in the pharmacy services and retail/LTC segments, and escalating drug prices are hampering the demand for CVS Health’s offerings. Further, the company is faced with stiff competition, especially in the pharmacy segment, as other retail businesses continue to add pharmacy departments and low-cost pharmacy options become available.

Zacks Rank and Key Picks

Currently, CVS Health carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the broader medical space are Baxter International Inc. BAX, Hologic, Inc. HOLX and Cerner Corporation CERN.

Baxter, currently carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 9.5%. Baxter’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 10.2%, on average. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Baxter has outperformed the industry over the past year. BAX has gained 9.7% against a 17.4% decline of the industry in the said period.

Hologic, carrying a Zacks Rank #2 at present, has a long-term earnings growth rate of 7.4%. HOLX surpassed earnings estimates in three of the trailing four quarters and missed in another occasion, delivering an average surprise of 29.2%.

Hologic has declined 10.1% compared with the industry’s 13% drop over the past year.

Cerner, carrying a Zacks Rank #2 at present, has a long-term earnings growth rate of 12.8%. CERN’s earnings surpassed estimates in three of the trailing four quarters and met estimates on another occasion, delivering an average surprise of 3.2%.

Cerner has gained 13.3% against the industry’s 57.6% slump over the past year.

P2P Meth: The Newest Product of the Meth Epidemic, and How We Got Here -INCREASING “meth” on our streets ?

P2P Meth: The Newest Product of the Meth Epidemic, and How We Got Here

https://www.hazeldenbettyford.org/articles/p2p-meth

The meth epidemic has taken a backseat in national attention because of the spotlight on opioids, but a new type of methamphetamine has created a spike in meth use. It’s known as P2P (phenyl-2-propanone) meth, and it’s the subject of recent debate: What makes P2P meth different from other forms of methamphetamine? What are its effects and dangers? How does it effect a person’s mental health? Can it cause serious mental illness?

To find the answers to those questions and more, read on.

Let’s cover the basics. What is methamphetamine?

Methamphetamine, usually referred to by its shorthand “meth,” is a central nervous system stimulant. Meth can be snorted, smoked, injected or taken orally, and its highs are characterized by an increase in energy and an elevated mood state. It is closely related, in both chemical structure and effect, to amphetamines, but meth has stronger effects and is usually manufactured illegally.

What’s the history behind meth and amphetamines?

Amphetamines have a long history of abuse that predates World War II, and soldiers on both sides allegedly abused the drug to help with fatigue. After the war, amphetamines were introduced and popularized across the United States when they were commonly prescribed by doctors to treat a variety of health conditions. In fact, amphetamines are still prescribed for ADD and ADHD, and less frequently for narcolepsy and weight loss.

When the crackdown on legally prescribed amphetamines began, the production of meth ramped up. The Comprehensive Drug Abuse Prevention and Control Act of 1970 limited people’s access to amphetamines, unintentionally creating a larger market for illegally manufactured methamphetamine.

Is this when the epidemic began?

Yes, the meth epidemic informally began in the 1970s when legislation limited the prescription of amphetamines. The production and use of illegal methamphetamine slowly traveled across the United States, starting on the West Coast and eventually, in the 1990s, finding a home in central and eastern parts of the country.

What did the illegal manufacturing of meth look like?

Also known as speed and glass, methamphetamine was initially cooked in home-grown laboratory set-ups, using cold medicine products that contained ephedrine. Meth made from ephedrine was readily available in the majority of the United States until the past decade when pharmacies became required by law to limit the sale of products containing ephedrine. Eventually, the Mexican government joined in outlawing ephedrine, thereby forcing drug traffickers to reinvent the process used to create methamphetamine.

What makes P2P meth different? Let’s look at the chemical makeup.

Since the crackdown on ephedrine-based cold remedies, the production of meth has changed, giving rise to newer chemical makeups like P2P meth. Replacing ephedrine, meth is now produced with chemicals like:

  • Acetone
  • Cyanide
  • Lye
  • Mercury
  • Sulfuric acid
  • Hydrochloric acid
  • Nitrostyerence
  • Racing fuel

Beyond just the ingredients, P2P meth also has a higher concentration of the isomer called d-methamphetamine. For reference, there are two forms of meth: d- and l-methamphetamine. Both are methamphetamines, obviously, but the two often come in different forms. The d-isomer is found in prescription drugs, whereas the l-isomer is found in over-the-counter products. And street drugs contain both, but generally contain more of the d-isomer because of its enhanced effects.

So what are the effects of this d-isomer in P2P meth?

The d-isomer produces the high, and the l-isomer affects the body. So P2P, with its heavy concentrations of d-isomer, creates a different and very intense high for its users.

Methamphetamine produced from ephedrine generally prompts those using it to stay up and socialize, sometimes for days, due to lower levels of the d-isomer. Whereas users of P2P meth experience very different effects, including severe mental illness, psychosis, the desire to isolate, and hallucinations or delusions.

The incalculable danger of P2P meth

Because the manufacturers of P2P meth often produce the drug in unhygienic environments and because the producers aren’t professional chemists, the consumers often suffer from additional and significant side effects. Street manufacturers’ main priority is making money, and they don’t generally worry about delivering a quality product.

Put simply, this new type of meth is more dangerous, and users have an increased likelihood of developing severe mental illness and other adverse mental health effects. P2P meth tends to be laced with other drugs like fentanyl, and users who seek help for their addiction have reported a detox process of nearly six months. Additionally, a person who uses P2P meth will likely experience a rapid decline in physical health, including liver failure, after even short periods using the substance.

Symptoms and side effects of P2P methamphetamines

Symptoms and side effects of P2P meth are similar to those of ephedrine-based meth. Meth changes the physiological and psychological functioning of the body and brain. Meth abuse causes heightened blood pressure, heart rate and respiratory rate. Psychological signs that a person might be using meth include temporary euphoria and energy, and increased levels of anxiety, paranoia, aggression, hallucinations and mood disturbances when dopamine levels taper off after use.

How to get help for an addiction to methamphetamines.

Treatment and recovery are available to all. There are specialized treatment services and programs to help with meth addiction, and there is a hopeful path forward from here. But it’s essential that you be evaluated by a medical professional before you begin the detoxification process. Seek an assessment for in-patient or outpatient treatment, and attend groups like AA, NA or other peer-driven recovery support groups. Addiction is not the end. If you are concerned about your own meth use or someone else’s, reach out for help today.

The Battle for America’s Prescription Drug System

The Battle for America’s Prescription Drug System

https://puttrx.medium.com/the-battle-for-americas-prescription-drug-system-4694e2195b71

Prescription drug cost is one of the few issues everyone can agree needs addressing, yet very few politicians seem able to abandon party-line rhetoric to confront the issue. Wealthy corporate campaign donations are now overriding basic common sense when it comes to reining in obvious systemic problems. Like climate change, we see political party leaders making promises, pointing fingers, but ultimately doing nothing. It’s as if no one can get out of their own way to focus on what’s really important — American patients.

It doesn’t help that the prescription drug industry itself seems more concerned with protecting trade secrets than allowing for actual transparency and issue resolution. From protecting formulas to hiding formularies, the prescription drug sector of America’s vertically-integrated oligarchy of a healthcare system is far closer to the steel and railroad monopolies of the early 1900s than an industry model for the 21st century.

Drug prices are high, so pharmacy benefit managers (PBMs) negotiate “rebates” — which are actually kickbacks — to include their drugs on plan formularies. Insurance companies claim they put patients first but maintain lucrative (for them) relationships with the PBMs.

Prescription drug costs are known to be among the highest healthcare spending points for employers. Local doctors, pharmacies, and hospitals are being taken over by PBM/insurance conglomerates, and those who hang their medical shingle as “independently-owned” face higher barriers to entry than in nearly any other industrial sector.

Where is the breaking point?

If our elected leaders could step above the fray for a moment, they would see it’s easy to draw a direct correlation between PBMs, skyrocketing prescription drug prices, and American healthcare degeneration. America is the only nation in the world that includes PBMs in healthcare, yet we have the highest prescription drug prices in the world.

Does anyone else see the common problem here?

The FTC and the DOJ are currently examining vertical integration legalities. It’s a good start, but it’s not enough. Unless our government is willing to kick healthcare campaign contributions to the curb and focus on what’s best for American patients, nothing will ever be solved.

I implore federal and state governments to mandate full transparency on EVERY aspect of the U.S. healthcare system from campaign contributions to how patient care costs are calculated. The people of this great nation deserve better, and are far more valuable than Wall Street dividends.

Shannon Wightman-Girard

PUTT Operations Manager, Independent Pharmacy Patient

Investigate Long Wait Times and Closures at Chain Pharmacies

Investigate Long Wait Times and Closures at Chain Pharmacies

https://resist.bot/petitions/pfdppx

In these unprecedented times, I ask you to immediately investigate closure decisions by corporate chain pharmacies, leading to long wait times and poor patient care. This directly and urgently impacts the health of my family and me. In the midst of a global pandemic, we don’t need more people in the hospital due to inaccessible medications. Such investigations should be required by law and immediately enforced due to the current high risk to public health.

In the last few months, I have experienced extremely long wait times in person and on the phone at a local chain pharmacy. Many have closed or have reduced hours, making it unpredictable and highly difficult to get medicines for myself and/or my loved ones. These medicines are important to maintain our health, or prevent events like a blood clot that could put us in the hospital. Imagine a day without necessary insulin. It is unsafe to go days without needed medicine, and extremely stressful and difficult to hunt around for an open pharmacy and call my doctor to transfer the prescription. The chain pharmacies seem constantly understaffed, often only having 1 or 2 people working behind the counter helping customers, answering phones, working the drive thru, and also giving COVID shots AND tests. This is not sustainable for the pharmacy staff, and THAT puts me and my family’s lives at risk.

PBM collateral damage: Veneta’s only pharmacy closes

IMG_0700.jpg

PBM collateral damage: Veneta’s only pharmacy closes

https://www.klcc.org/2022-01-28/venetas-only-pharmacy-closes

Veneta’s only pharmacy closed on January 5th, leaving the township of over 5,000 without a convenient way to fill their prescriptions.

91-year-old Derek Humphry has nine prescriptions he needs to fill regularly, including heart medication. He’s been a resident of Veneta for 32 years.

Last year, when Bi-Mart’s pharmacy was acquired by Walgreens, 56 counters closed in three states, including the only pharmacy in Veneta.

Humphry tried several others in the area and was turned away without explanation. He was within two days of running out of his blood-thinning medication when his doctor directed him to a Walmart in Eugene, significantly further away.

“A person like me doesn’t drive,” Humphry said. “I have to get other people to take me to the pharmacy. So it’s quite inconvenient.”

Bi-Mart spokesperson Don Leber attributes their exit from the pharmacy business to Oregon taxes on pharmaceuticals and increased fees implemented by insurance companies and pharmacy benefit managers.

“Those two elements have made it so we can no longer operate our pharmacies and make any profits,” Leber told KLCC.

good ole opiophobic Ohio: Doctors office in Niles closed due to FBI raid

good ole opiophobic Ohio: Doctors office in Niles closed due to FBI raid

https://www.wfmj.com/story/45743467/niles-fbi-raid

A doctor’s office in Niles is closed after the Federal Bureau of Investigation conducted a raid of its offices. 

Internal Medicine Dr. Jeffery Sutton’s office has a sign on the door notifying patients that the office is closed due to a federal search warrant. 

The FBI would only say that  the raid is for the “purposes of law enforcement activity.” 

21 News will update this story with any new information. 

 

CVS: 1.2 Billion IN FINES for 452 violations since 2000 – how many violations didn’t get CAUGHT ?

Philly to start tracking doctors to target opioid over prescribers

This appears to be a DISASTER IN THE MAKING… we have bureaucrats ( Philadelphia health officials ) that are going to make determination as to what is “OVER-PRESCRIBING OF OPIATES ”  based on some pretty much RAW DATA.  What if those prescribers that they are already targeting – very small number of physicians  in the area are responsible for most of the over prescribing – are all chronic pain practitioners/clinics ?   This is after in a two year period According to city data, the number of opioid prescriptions decreased by 30% between early 2017 and early 2019… Does this suggest that their final target maybe near ZERO OPIATES PRESCRIBED for acute pain and maybe only “token doses” for chronic pain long term ?

Philly to start tracking doctors to target opioid over prescribers

https://whyy.org/articles/philly-to-start-tracking-doctors-to-target-opioid-overprescribers/

Despite their yearslong effort to urge doctors to prescribe fewer opioids, Philadelphia health officials say there are still too many pills being dispensed in the region. They know from state data, provided by the Pennsylvania prescription drug monitoring database, that a very small number of physicians in the area are responsible for most of the over prescribing. But because the state data does not include identifying information, local officials have no way of knowing who to go after.

Thanks to new legislation passed during Philadelphia’s last 2019 City Council session, that’s about to change.

In 2018, health officials issued new prescribing guidance to more than 15,000 doctors in the Philadelphia region. Health Commissioner Thomas Farley said his department sent staff into more than 1,000 offices to work directly with doctors to curb prescriptions and come up with alternative approaches to pain management. By most accounts, it’s working: According to city data, the number of opioid prescriptions decreased by 30% between early 2017 and early 2019.

Even so, Farley said, there are still too many prescription drugs floating around.

“We find that, despite the large amounts of publicity, there are still some doctors out there that don’t understand that their prescribing practices really aren’t good for their patients in the long run,” he said. “They were taught for years to prescribe more opioids.”

Farley said he can tell from the regular reports he gets from the state’s prescription drug monitoring program that most of the city’s opioids are coming from just a few doctors. Roughly 1% of the doctors write a quarter of all opioid prescriptions, and another 10% write half of them. Half of the doctors don’t ever prescribe opioids.

The only problem is, the city knows this from a consolidated report issued by the state that doesn’t include the physicians’ names.

“We can use that for statistics, but we can’t use that for educating individual physicians,” said Farley.

The new law will require pharmacies to send regular dispatches to the city Health Department for all controlled-substance prescriptions. The report will include the name of the prescribing doctor, the type of drug, how much is being prescribed, and how often. Pharmacies will also have to create a unique identification number for each patient, protecting that patient’s anonymity but still tracking patterns.

If health officials notice a pattern of overprescribing, a physician will be flagged and receive education from the Health Department. The city will then be able to track whether the doctor’s prescriptions went down over the next reporting period. If they don’t, Farley said, the Health Department will work with law enforcement to come up with appropriate consequences.

(Philadelphia Health Department)

Prescription data-monitoring databases have been criticized for their potential to serve as a direct line between vulnerable patients and law enforcement. While the Philadelphia version won’t identify individual patients, critics have also expressed concern that if doctors know they are being closely monitored, they might be hesitant to prescribe a controlled substance even if it is the best option for the patient. If patients who have become dependent on opioids are tapered off too quickly, research has shown they may turn to less-regulated, illicit opioids such as heroin and fentanyl where the risk of overdose is higher.

Farley stressed that because the effort is specifically to target that subsection of high prescribers, he did not anticipate this being an issue.

Eva Gladstein, the city’s deputy managing director of health and human services, said they wouldn’t have gone the legislative route if they didn’t have to. But the state regulations are narrowly written, she said, and while state officials can see prescribers by name, they interpreted the law as not permitting them to share that information with municipal departments.

“I would say we spent two years working with the state to see if we could get the data so we didn’t need to do this,” Gladstein said.

Farley said the new program was still a few months away from rolling out because they still have to come up with the exact reporting regulations. He said one pharmacy chain was dragging its feet about adopting the new law, but declined to say which.

Georgia HB 867: requires PBMs to calculate patient cost sharing for prescription drugs based on true costs to plans

House Chairman and physician Mark Newton introduced HB 867, which requires PBMs to calculate patient cost sharing for prescription drugs based on true costs to plans, by taking into account rebates PBMs receive from pharmaceutical manufacturers. PBMs are in opposition to this legislation and trying to point the finger at independent pharmacies for rising drug costs at the counter.
The bill is scheduled for a hearing tomorrow in Chairman Newton’s Special Committee on Access to Quality Healthcare. Below are members of that Committee. Please reach out to committee members prior to 2:00 pm tomorrow and let them know:
1. You are in support in support of HB 867, as it will reduce prices for Georgia patients at the counter by requiring PBMs to factor in rebates received when calculating a patient’s cost share;
2. If PBMs are negotiating rebates, patients should receive the benefit of those discounts at the counter and should not pay cost shares based in inflated pricing at the drug counter; and
3. Community pharmacies do not benefit in any way from this legislation financially, but you are in support because this legislation increases drug pricing transparency and reduces drug costs for patients at the counter.
Special Committee on Access to Quality Healthcare:
david.knight@house.ga.gov 404.463.2248
patty.bentley@house.ga.gov 404.656.0287
sharon.cooper@house.ga.gov 404.656.5069
john.corbett@house.ga.gov 404.656.5105
spencer.frye@house.ga.gov 404.656.0265
matt.hatchett@house.ga.gov 404.656.5025
penny.houston@house.ga.gov 404.463.2248
todd.jones@house.ga.gov 404.463.2246
randy.nix@house.ga.gov 404.656.5146
larry.parrish@house.ga.gov 404.463.2246
clay.pirkle@house.ga.gov 404.656.7850
brian.prince@house.ga.gov 404.656.0116
richard.smith@house.ga.gov 404.656.5141
calvin.smyre@house.ga.gov 404.656.0109
mark.newton@house.ga.gov 404.656.7853

Political Science: DeSantis SLAMS Biden’s FDA for Abruptly Closing Florida’s ‘Lifesaving’ Treatment Sites ?

Political Science: DeSantis SLAMS Biden’s FDA for Abruptly Closing Florida’s ‘Lifesaving’ Treatment Sites ?

https://www.toddstarnes.com/politics/desantis-fda-biden-monoclonal-antibody-treatment-sites/

Florida Gov. Ron DeSantis (R) is demanding the Biden administration reverse its “sudden and reckless” decision to pull Emergency Use Authorizations for monoclonal antibody treatments.

The Food and Drug Administration (FDA) cut off Florida’s monoclonal antibody treatment sites Monday, citing the omicron variant, impacting more than 2,000 Floridians who had treatments scheduled Tuesday.

“Without a shred of clinical data to support this action, Biden has forced trained medical professionals to choose between treating their patients or breaking the law,” DeSantis said in a statement.

“This indefensible edict takes treatment out of the hands of medical professionals and will cost some Americans their lives,” he added. “There are real-world implications to Biden’s medical authoritarianism – Americans’ access to treatments is now subject to the whims of a failing president.”

The Florida Department of Health said it was not given any advanced notice of the FDA’s “abrupt” decision to pull the treatments that can prevent severe illness, hospitalization, and death in high-risk patients who get COVID.

“As a result of the @US_FDA’s abrupt decision to remove the EUAs for two monoclonal antibodies, monoclonal antibody treatment sites will be closed until further notice,” it wrote. “Florida disagrees with the decision that blocks access to any available treatments in the absence of clinical evidence.”

“Rather than giving Americans the option for various COVID treatments, the FDA and the Biden Administration issued their royal decree, taking away the very thing that is proven to reduce hospitalizations and save lives,” said Lieutenant Governor Jeanette Nuñez. “Monoclonal antibody treatments like Regeneron have had a positive impact for thousands of Floridians. For the CDC and FDA, which have been consistently inconsistent throughout the entire pandemic, to restrict treatment does nothing but put individuals at risk.”

“In our field of medicine, when someone comes to you seeking a treatment that could save their life, it is essential to have treatment options to ensure health care providers can make the best decisions for their patients,” said Surgeon General Dr. Joseph Ladapo. “The Federal Government has failed to adequately provide the United States with adequate outpatient treatment options for COVID-19. Now, they are scrambling to cover up a failure to deliver on a promise to ‘shut down the virus.’”

DeSantis has been an advocate for the treatments from Regeneron and Eli Lily, and he said last year that “come hell or high water” he will fight to get them despite the Biden administration seizing the supply of Regeneron and cutting supply to Florida.

The FDA said it pulled the emergency use “because data shows these treatments are highly unlikely to be active against the omicron variant.”

“Sick,” Jack Posobiec, Human Events Daily host, tweeted along with the story.

“The FDA is trying to make it so that people in Florida die of Covid. They’ll kill people to harm Republicans,” Mike Cernovich tweeted. “Steel yourselves for the evil that is being unleashed.”

New treatment sites were opened in the Sunshine State just last week.